VLDB 2026 Research / reviewers in the wild / expert
Lixiang Hong
dblp:232/6286
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2019
0000-0002-4753-7660ORCID · reported
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% | |
| Artificial intelligence
1 paper |
Graph learning · 100% |
Topics — the 3 heaviest of 3, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery
drug-target interaction prediction |
0.4 | 1 | 2019 | NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactions · Bioinform. 2019 |
Bioinformatics and computational biology › data integration
heterogeneous network integration |
0.4 | 1 | 2019 | NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactions · Bioinform. 2019 |
Machine learning › Graph learning › network embedding
heterogeneous graph embedding |
0.1 | 1 | 2019 | NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactions · Bioinform. 2019 |
Methods — techniques the papers use, named apart from their topics
information passing and aggregation · 0.8graph neural network · 0.8
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2019 | NeoDTI: neural integration of neighbor information from a heterogeneous network for discovering new drug-target interactionsabstractMotivation: Accurately predicting drug-target interactions (DTIs) in silico can guide the drug discovery process and thus facilitate drug development. Computational approaches for DTI prediction that adopt the systems biology perspective generally exploit the rationale that the properties of drugs and targets can be characterized by their functional roles in biological networks. Results: Inspired by recent advance of information passing and aggregation techniques that generalize the convolution neural networks to mine large-scale graph data and greatly improve the performance of many network-related prediction tasks, we develop a new nonlinear end-to-end learning model, called NeoDTI, that integrates diverse information from heterogeneous network data and automatically learns topology-preserving representations of drugs and targets to facilitate DTI prediction. The substantial prediction performance improvement over other state-of-the-art DTI prediction methods as well as several novel predicted DTIs with evidence supports from previous studies have demonstrated the superior predictive power of NeoDTI. In addition, NeoDTI is robust against a wide range of choices of hyperparameters and is ready to integrate more drug and target related information (e.g. compound-protein binding affinity data). All these results suggest that NeoDTI can offer a powerful and robust tool for drug development and drug repositioning. Availability and implementation: The source code and data used in NeoDTI are available at: https://github.com/FangpingWan/NeoDTI. Supplementary information: Supplementary data are available at Bioinformatics online. Fangping Wan, Lixiang Hong, An Xiao, Tao Jiang 0001, Jianyang Zeng 0001 |
Bioinform. | 2 |